Karapetis, C. S. http://orcid.org/0000-0003-1741-996X
Liu, H.
Sorich, M. J. http://orcid.org/0000-0003-1999-866X
Pederson, L. D.
Van Cutsem, E. http://orcid.org/0000-0002-6372-1230
Maughan, T. http://orcid.org/0000-0002-0580-5065
Douillard, J. Y.
O’Callaghan, C. J.
Jonker, D.
Bokemeyer, C.
Sobrero, A.
Cremolini, C. http://orcid.org/0000-0002-0520-4841
Chibaudel, B.
Zalcberg, J. http://orcid.org/0000-0002-6624-0782
Adams, R.
Buyse, M.
Peeters, M.
Yoshino, T. http://orcid.org/0000-0002-0489-4756
de Gramont, A.
Shi, Q.
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1085364)
Article History
Received: 26 September 2023
Revised: 22 January 2024
Accepted: 29 January 2024
First Online: 24 February 2024
Competing interests
: Karapetis CS declares an advisory board role for Roche, Amgen and Merck Serono. Liu H declares no potential competing interests. Sorich M declares research grants received from Pfizer. Pederson LD declares no potential competing interests. Van Cutsem E declares participation to advisory boards for Abbvie, ALX, Amgen, Array, Astellas, AstraZeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seattle Genetics, Servier, Takeda, Terumo, Taiho, Zymeworks. He also declares research grants from Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier paid to his institution. Maughan T declares that he has consulted for AstraZeneca, Nordic Pharma and Ground Truth Laboratories. Douillard JY declares no potential competing interests. O’Callaghan CJ declares no potential competing interests. Jonker D declares no potential competing interests. Bokemeyer C declares advisory board involvement for Astra Zeneca, Bayer, BioNTech, BMS, Jansen Cilag, Merck Serono, Oncology Drug Consult CRO, and Sanofi Aventis. He also declares compensation as an invited speaker for AOK Germany, Med Update and Roche Pharma. Sobrero A declares advisory board and speaker at satellites for Roche, Merck, Amgen, Bayer, Sanofi, Servier, BMS, MSD. Cremolini C declares an advisory board role with Merck Serono, MSD, Nordic Pharma, Roche, Pierre Fabre and Takeda, and she has been an invited speaker with compensation for Amgen, Bayer, Merck Serono, MSD, Pierre Fabre and Servier. She also declares that she is a local principal investigator on trials sponsored by Bayer, Hutchinson, Merck, Roche, Seagen and Servier. Chibaudel B declares no potential competing interests. Zalcberg J declares leadership roles with ICON Group, Lipotek and Praxis. He declares stock ownership of BioMarin, Opthea, Amarin, Concert Pharmaceuticals, Frequency Therapeutics, Gilead, Madrigal Pharmaceuticals, uniQure, Zogenix, Orphazyme, Moderna Therapeutics, TWST, Novavax and Teladoc. He declares honoraria received from Gilead Sciences, MSD Oncology and Viatris. He declares a consulting or advisory role for MSD, CEND, Deciphera, Revolution Medicine, Specialised Therapeutics, FivepHusion, Genorbio, 1Global, Novotech, Alloplex Biotherapeutics Inc, NOUS Consulting and Oncology Republic. He has received paid travel and accommodation expenses from MSD Oncology, ICON Group and PRAXIS. Adams R declares conference attendance fees paid by Amgen. Buyse M declares stock ownership in IDDI (International Drug Development Institute, Belgium). Peeters M<sup>16</sup> declares no potential competing interests. Yoshino T declares honoraria received from Chugai Pharma, Takeda Pharma, Merck, Bayer Yakuhin, Ono Pharmaceutical and MSD K.K; Consulting Fee from Sumitomo Corp.; Research Grant/Funding from Amgen, Chugai, Daiichi Sankyo, Eisai, FALCO Biosystems, Genomedia Inc., Molecular Health, MSD, Nippon Boehringer Ingelheim, Ono, Pfizer, Roche Diagnostics, Sanofi, Sysmex and Taiho de Gramont A declares no potential competing interests. Shi Q declares consulting/advisory role from Yiviva Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Hoosier Cancer Research Network, Kronos Bio, and Mirati Therapeutics Inc.; Honorarium/speaker role from Chugai Pharmaceutical Co., Ltd.
: The ARCAD database collaboration research protocol was approved by the Mayo Clinic Institution Review Board. All patients had consented to take part in the randomised controlled trials from which the data was collected and stored in the ARCAD database.